VAV1 (Ab-174) Antibody

What is the VAV1 (Ab-174) Antibody and what epitope does it recognize?

VAV1 (Ab-174) Antibody is a rabbit polyclonal antibody designed to detect endogenous levels of total VAV1 protein. The antibody specifically recognizes a peptide sequence surrounding amino acid residues 172-176 (E-I-Y-E-D) of human VAV1. This sequence is critical for VAV1 function as it contains the important tyrosine 174 residue that undergoes phosphorylation during T cell activation and signaling pathways . The antibody has been purified using affinity chromatography with an epitope-specific peptide to ensure high specificity to the target sequence, making it valuable for studying VAV1 expression in various experimental systems .

In which research applications can the VAV1 (Ab-174) Antibody be effectively used?

The VAV1 (Ab-174) Antibody has been validated primarily for Western blot (WB) applications, where it can effectively detect the ~95 kDa VAV1 protein . Some formulations of this antibody are also suitable for immunohistochemistry (IHC) applications, allowing researchers to visualize VAV1 expression in tissue sections . The antibody demonstrates reactivity with human and rat samples, making it versatile for cross-species investigations . Western blot validation data shows successful detection of VAV1 protein in Jurkat (JK) cell extracts, confirming its utility in human T cell research models, which are particularly relevant given VAV1's significant role in T cell signaling and activation .

How can I design experiments to study VAV1 phosphorylation dynamics in T cell activation using VAV1 (Ab-174) Antibody?

For studying VAV1 phosphorylation dynamics, design a time-course experiment with TCR stimulation of T cells (e.g., Jurkat cells). First, establish baseline total VAV1 levels using the VAV1 (Ab-174) Antibody in Western blots . Then monitor changes in phosphorylation at different time points after stimulation using a phospho-specific antibody targeting Tyr174 . Calculate the phospho-VAV1/total VAV1 ratio to quantify activation kinetics. Recent research on Vav1-Myo1f expression shows significantly increased VAV1 phosphorylation at Tyr174 in CD4+ T cells, correlating with enhanced TCR signaling, ERK1/2 phosphorylation, cytokine secretion, and T cell proliferation . Include appropriate controls such as unstimulated cells and phosphatase inhibitor treatment to prevent artificial dephosphorylation during lysate preparation. This approach provides mechanistic insights into how VAV1 activation contributes to downstream T cell functions.

What are the considerations for studying VAV1 in oncogenic transformation versus normal T cell development?

When investigating VAV1's roles in oncogenic transformation versus normal development, several experimental design factors are critical. First, establish baseline VAV1 expression in normal lymphoid tissues using the VAV1 (Ab-174) Antibody, which detects endogenous levels of total VAV1 protein regardless of phosphorylation state . Then examine both expression levels and phosphorylation status (using phospho-Tyr174 specific antibodies) in transformed cells . Recent research demonstrates that oncogenic Vav1-Myo1f fusion proteins exhibit markedly increased phosphorylation at Tyr174, enhancing TCR signaling, proliferation, and resistance to cytokine withdrawal-induced apoptosis . Design experiments to assess downstream signaling partners including ERK1/2 phosphorylation, which was significantly elevated in cells expressing oncogenic VAV1 variants . Include functional assays measuring proliferation, activation marker expression (CD69, CD25), and survival under stress conditions to differentiate between normal and oncogenic VAV1 activity patterns . This comprehensive approach helps distinguish physiological from pathological VAV1 signaling.

How can I validate the specificity of VAV1 (Ab-174) Antibody for phosphorylation-independent detection in complex experimental systems?

To validate the phosphorylation-independent specificity of VAV1 (Ab-174) Antibody, implement a multi-faceted approach. Start with phosphatase treatment of cell lysates to dephosphorylate all proteins, then compare detection levels between treated and untreated samples using both the VAV1 (Ab-174) Antibody and a phospho-specific anti-VAV1 (phospho Tyr174) antibody . The VAV1 (Ab-174) Antibody should show consistent detection regardless of phosphatase treatment, while the phospho-specific antibody should show diminished signal in treated samples. Additionally, perform competition assays using the immunizing peptide sequence (around aa. 172-176, E-I-Y-E-D) to confirm epitope-specific binding . Further validation can include VAV1 knockdown or knockout controls, where the signal should be substantially reduced or eliminated. In advanced systems, comparing detection in cells with mutations at Tyr174 that prevent phosphorylation can provide definitive evidence of phosphorylation-independent recognition. This comprehensive validation ensures reliable interpretation of results in complex experimental models studying VAV1 biology.

What are the optimal conditions for Western blot detection of VAV1 using the VAV1 (Ab-174) Antibody?

For optimal Western blot detection of VAV1 using the VAV1 (Ab-174) Antibody, follow these methodological guidelines based on validated protocols. Prepare cell or tissue lysates in a buffer containing phosphatase inhibitors to preserve phosphorylation states and load 25-30μg of protein per lane on an 8-10% SDS-PAGE gel to achieve good resolution of the ~95kDa VAV1 protein . After transfer to PVDF or nitrocellulose membranes, block with 3-5% BSA in TBST (preferred over milk for phosphoprotein detection) . Dilute the VAV1 (Ab-174) Antibody at 1:500-1:2000 in blocking buffer and incubate overnight at 4°C for maximum sensitivity . For detection, use HRP-conjugated anti-rabbit secondary antibody (1:10,000 dilution) followed by enhanced chemiluminescence visualization . The expected band size for VAV1 is approximately 95kDa, and validation data shows successful detection in Jurkat cell extracts . For multi-protein detection, strip and reprobe membranes or use fluorescent secondary antibodies for simultaneous detection of multiple targets, including loading controls such as β-actin or GAPDH.

What considerations should be made when using the VAV1 (Ab-174) Antibody in combination with phospho-specific antibodies?

When using VAV1 (Ab-174) Antibody in combination with phospho-specific antibodies, several methodological considerations are essential for accurate results. First, ensure proper sample preparation by using phosphatase inhibitors in lysis buffers to preserve phosphorylation states . For sequential detection on the same membrane, determine whether to start with the phospho-specific antibody or the total VAV1 antibody; generally, begin with the phospho-specific anti-VAV1 (phospho Tyr174) antibody due to its higher sensitivity to epitope changes . When stripping membranes between probings, use mild stripping conditions that remove antibodies without affecting proteins and validate stripping efficiency before reprobing. Alternatively, use fluorescently-labeled secondary antibodies with distinct emission spectra to simultaneously detect total and phosphorylated VAV1 if the primary antibodies originate from different host species. For quantitative analysis, calculate the ratio of phosphorylated to total VAV1 to normalize for expression level variations between samples, as demonstrated in research examining increased VAV1 phospho-Tyr174 in VAV1-Myo1f expressing cells . Finally, include appropriate controls such as unstimulated cells (low phosphorylation) and strongly stimulated samples (high phosphorylation) to establish the dynamic range of your detection system.

How can I optimize immunohistochemistry protocols using VAV1 (Ab-174) Antibody for tissue samples?

For optimizing immunohistochemistry protocols using VAV1 (Ab-174) Antibody, begin with antigen retrieval optimization, as VAV1 epitopes may be masked during fixation. Test both heat-induced epitope retrieval methods (citrate buffer pH 6.0 and EDTA buffer pH 9.0) and enzymatic retrieval to determine which best exposes the epitope around amino acids 172-176 (E-I-Y-E-D) . Optimize antibody concentration through a dilution series (typically starting at 1:100-1:500) and incubation conditions (4°C overnight versus room temperature for various durations) . Select appropriate detection systems based on tissue type and expression levels; amplification systems like tyramide signal amplification may be beneficial for low-abundance VAV1 expression. Include positive control tissues with known VAV1 expression (e.g., lymphoid tissues, particularly T-cell rich regions) and negative controls (primary antibody omission and isotype controls) . For dual staining to correlate VAV1 expression with T-cell markers or phosphorylation status, use sequential detection protocols with appropriate blocking steps between antibody applications. Finally, validate staining patterns by comparing results with published literature on VAV1 expression patterns in lymphoid tissues and confirm specificity using tissues from VAV1-deficient models when available.

What are common issues in Western blot detection using VAV1 (Ab-174) Antibody and how can they be resolved?

When troubleshooting Western blots with VAV1 (Ab-174) Antibody, several common issues may arise. For weak or absent signals, first verify protein loading with housekeeping controls and consider longer exposure times or increased antibody concentration (up to 1:500 dilution) . If non-specific bands appear, optimize blocking conditions using 3% BSA as demonstrated in validation studies rather than milk proteins, which can interfere with phosphoprotein detection . For high background, increase washing duration and frequency with TBST and reduce secondary antibody concentration. When detecting VAV1 in different species, note that this antibody is validated for human and rat samples; detection in other species may require sequence homology verification around the epitope (aa 172-176) . If comparing phosphorylated versus total VAV1, remember that aberrant migration patterns may occur due to phosphorylation-induced conformational changes, as observed in studies of Vav1-Myo1f where phosphorylation status affected protein mobility . For technical verification, the expected molecular weight of VAV1 is approximately 95kDa, and validation data confirms detection in Jurkat cell lines, making these appropriate positive controls . Finally, store the antibody according to manufacturer recommendations (-20°C for long term) and avoid repeated freeze-thaw cycles to maintain activity.

How should I interpret discrepancies between total VAV1 levels and phospho-VAV1 (Tyr174) levels in experimental samples?

When interpreting discrepancies between total VAV1 levels (detected by VAV1 (Ab-174) Antibody) and phospho-VAV1 (Tyr174) levels, consider several biological and technical factors. First, these differences often reflect genuine biological regulation, as VAV1 phosphorylation is dynamically controlled during T cell activation independent of expression levels . In research examining Vav1-Myo1f expression, significant increases in Tyr174 phosphorylation were observed despite modest changes in total VAV1, representing enhanced activation rather than expression changes . Technical considerations include differential antibody affinities; phospho-specific antibodies may have different binding efficiencies than total protein antibodies, necessitating standard curves with known quantities of both forms for accurate quantification . Verify results using multiple detection methods and normalize phospho-signal to total protein signal for each sample to account for expression variations. Consider that phosphorylation can create conformational changes affecting epitope accessibility for the total VAV1 antibody, particularly since the VAV1 (Ab-174) Antibody targets a region (aa 172-176) that includes the phosphorylation site itself . Finally, examine the broader signaling context by assessing downstream effectors like ERK1/2 phosphorylation, which typically correlates with VAV1 activation states as demonstrated in published research .

How can I distinguish between VAV1 isoforms or confirm detection of VAV1-fusion proteins?

To distinguish between VAV1 isoforms or confirm detection of VAV1-fusion proteins, implement a multi-faceted analytical approach. First, utilize gradient SDS-PAGE gels (6-12%) to achieve optimal resolution of different molecular weight variants; native VAV1 is approximately 95kDa, while fusion proteins like Vav1-Myo1f will show altered molecular weights . Perform parallel Western blots with antibodies targeting different VAV1 domains - the VAV1 (Ab-174) Antibody recognizes the region around amino acids 172-176, so combining it with antibodies targeting N-terminal or C-terminal regions can confirm fusion protein identity . For definitive characterization, consider immunoprecipitation with the VAV1 (Ab-174) Antibody followed by mass spectrometry analysis to determine the exact composition of the detected protein. In cases studying known fusion proteins like Vav1-Myo1f, design PCR primers spanning the fusion junction for transcript verification alongside protein detection . For functional validation, examine phosphorylation patterns, as fusion proteins often show aberrant phosphorylation states; the Vav1-Myo1f fusion exhibits markedly increased phosphorylation at Tyr174 compared to wild-type VAV1 . Finally, analyze downstream signaling outputs such as ERK1/2 phosphorylation, which differs between wild-type VAV1 and fusion variants, providing additional confirmation of variant-specific activity .

How can VAV1 (Ab-174) Antibody be used to investigate the relationship between VAV1 and T cell differentiation pathways?

To investigate VAV1's role in T cell differentiation using VAV1 (Ab-174) Antibody, design experiments that correlate VAV1 expression and activation with T cell subset development. First, isolate CD4+ T cells and culture them under polarizing conditions for various helper subsets (Th1, Th2, Tfh, Treg). At defined timepoints, perform Western blot analysis using the VAV1 (Ab-174) Antibody to quantify total VAV1 expression across differentiation stages . In parallel, assess phosphorylation at Tyr174 using phospho-specific antibodies to determine activation status . Research on Vav1-Myo1f expression has revealed that altered VAV1 signaling significantly impacts helper T cell specification, with notable increases in CXCR5+PD1+ Tfh cells, FOXP3+ regulatory T cells, and CXCR3+ Th1 populations . For mechanistic insights, combine these analyses with measurement of downstream signaling events, including ERK1/2 phosphorylation and cytokine production profiles characteristic of each T cell subset . Flow cytometric analysis of surface markers can be correlated with biochemical data to link VAV1 expression levels to specific differentiation states. Consider using VAV1 inhibitors or expression of dominant-negative constructs to establish causality between VAV1 activity and differentiation outcomes, validating observations with the antibody-based detection of signaling states.

What methodological approaches can be used to study VAV1 involvement in T cell receptor (TCR) signaling complexes?

To investigate VAV1's role in TCR signaling complexes, employ multi-dimensional approaches using VAV1 (Ab-174) Antibody. Begin with co-immunoprecipitation experiments where TCR complexes are precipitated after stimulation, followed by immunoblotting with VAV1 (Ab-174) Antibody to detect associated VAV1 . For temporal dynamics, perform time-course experiments following TCR engagement, analyzing both total VAV1 and phospho-Tyr174 levels, as research shows rapid phosphorylation kinetics at this site during T cell activation . Implement proximity ligation assays (PLA) to visualize in situ interactions between VAV1 and other TCR signaling components, using the VAV1 (Ab-174) Antibody paired with antibodies against ZAP70, LAT, or SLP76. Advanced approaches include blue native PAGE to preserve intact protein complexes, followed by immunoblotting to identify VAV1-containing complexes of different molecular weights. Research on oncogenic Vav1-Myo1f has demonstrated enhanced TCR signaling outcomes, including increased ERK1/2 phosphorylation, cytokine secretion, and proliferation, providing important positive controls for functional validation . For spatial organization studies, use immunofluorescence microscopy with the VAV1 (Ab-174) Antibody to track VAV1 recruitment to the immunological synapse during T cell activation, potentially combining with super-resolution techniques for nanoscale resolution of signaling clusters.

How can VAV1 (Ab-174) Antibody be utilized in studying the oncogenic potential of VAV1 mutations or fusions?

For investigating the oncogenic potential of VAV1 mutations or fusions, VAV1 (Ab-174) Antibody serves as a critical tool within a comprehensive research strategy. Begin by establishing model systems expressing wild-type VAV1 versus mutant/fusion variants (such as Vav1-Myo1f) in appropriate cell lines or primary cells . Use the VAV1 (Ab-174) Antibody for Western blot analysis to confirm expression levels and compare with phospho-Tyr174 status, as hyperphosphorylation at this site has been documented in oncogenic VAV1 variants . The antibody's specificity for the region around amino acids 172-176 makes it particularly valuable for studying mutations affecting this regulatory domain . Design transformation assays measuring proliferation, resistance to apoptosis, and colony formation capacity, correlating these phenotypes with biochemical data from VAV1 detection. Research has demonstrated that Vav1-Myo1f expression leads to increased T cell activation (elevated CD69 and ICOS expression), enhanced ERK1/2 phosphorylation, and resistance to cytokine withdrawal-induced apoptosis - all hallmarks of oncogenic potential that can be monitored alongside VAV1 detection . For in vivo studies, engineer mouse models expressing VAV1 variants and use immunohistochemistry with the antibody to track expression patterns in developing lymphomas. Integrate these approaches with genomic and transcriptomic analyses to establish comprehensive mechanistic models of how specific VAV1 alterations drive oncogenic transformation in lymphoid malignancies.